VAP treatment cost after cardiac surgery
Research type
Research Study
Full title
Cost-benefit analysis for treatment of Ventilator-Associated-Pneumonia (VAP) in patients undergoing cardiac surgery patients in the UK
IRAS ID
183629
Contact name
Heyman Luckraz
Contact email
Sponsor organisation
New Cross Hospital, Wolverhampton
Duration of Study in the UK
0 years, 5 months, 31 days
Research summary
This study is set up to estimate the cost of treating ventilator associated pneumonia (VAP) in patients after cardiac surgery and assess whether the use of a new endotracheal tube (ETT) would be cost-beneficial.
Data which was prospectively collected on electronic databases during patient's stay when they underwent cardiac surgery will be retrieved to enable a thorough costing for the patient's in-hospital stay. Some data may need to be accessed from the patients medical records.
Patients who underwent cardiac surgery from 2011 to 2014 (around 3000 patients) and who developped VAP will be selected (around 340 patients - study group). They will be propensity-matched to those who did not develop VAP (around 340 patients - control group). Data will then be retrieved from various hospital databases (PATS Dendrite, TD-Web, Web Portal, iSite, Medtrack).Data pertaining to post-op recovery including any complications, length of ICU and ward stays, antibiotic usage, additional respiratory support and survival will be collected.
So far, the ETT used is the Portex tube which cost £1.50 but is associated with VAP in up to 25% of patients after cardiac surgery. The new ETT is the PneuX ETT is associated with 10% VAP in a similar group of patient but cost around £100.REC name
West of Scotland REC 3
REC reference
15/WS/0142
Date of REC Opinion
9 Jul 2015
REC opinion
Favourable Opinion